Rituximab Induced Late Onset Neutropenia
K. H. B. P. Fernandopulle & J. Bavanthan · International Journal of Research and Reports in Hematology · 2022
Rituximab is a monoclonal antibody against CD20 a leucocyte cell marker expressed on normal and neoplastic B lymphocytes .Although first used for treatment of CD20 positive non-hodgkin’s lymphoma it’s use has expanded to include a varied spectrum of diseases mostly autoimmune dis...
Open access
Research Article